A Phase 3 interventional study of Placebo and Tocilizumab in Systemic Sclerosis, sponsored by Hoffmann-La Roche. Completed at 83 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 19th largest by enrollment of the 142 interventional ones that give a count, is one of 7 that started in 2015, is one of 12 in phase 3, and was the 69th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
Drug: Placebo · Drug: Tocilizumab
Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
Drug: Tocilizumab
Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period
The efficacy of TCZ vs placebo is evaluated in terms of in mean change in mRSS. Skin thickness will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.
Time frame: From baseline to week 48
Percentage of Participants With Greater Than or Equal to (>/=) 20%, 40%, or 60% Improvement in mRSS During Double-blind Period
The proportion of participants with threshold improvements in mRSS at Week 48 relative to baseline.
Time frame: From Baseline to Week 48
Change From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period
FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.
Time frame: Baseline to week 48
Change in Forced Vital Capacity (FVC) During Double-blind Period
FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.
Time frame: From Baseline to Week 48
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period
The Health Assessment Questionnaire Disability Index (HAQ-DI) consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The total score indicates the patient's self-assessed level of disability. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.
Time frame: From Baseline to Week 48
Change in Patient Global Assessment Score During Double-blind Period
The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."
Time frame: From Baseline to Week 48
Change in Physician Global Assessment Score During Double-blind Period
The Physician's Global Assessment is to be completed on the basis of examination and overall assessment of the patient. The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."
Time frame: From Baseline to Week 48
Time to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind Period
Time to treatment failure is defined as the time from randomization to the time of death, decline in percent-predicted FVC \> 10% relative to baseline, \> 20% increase in mRSS and an increase in mRSS of equal to or more than 5 points, or occurrence of a predefined SSc-related complication as adjudicated by the Clinical Adjudication Committee (whichever occurs first) during the 48-week double-blind treatment period. The median TTF was not estimable and is not presented for either treatment arm because of the low number of patients with events at Week 48.
Time frame: From Baseline to Week 48
Summary of Adverse Events During Double-blind Period
Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 20.1. NMSC = Non-Melanoma Skin Cancer
Time frame: From Baseline until Week 48
Incidence and Severity of Adverse Events During Double-blind Period
Adverse events listed according to MedDRA version 20.1 preferred terms and severity grade.
Time frame: From Baseline until Week 48
Number of Participants With Adverse Events Leading to Death During Double-blind Period
Reason of death is coded using MedDRA 20.1
Time frame: From Baseline up to Week 48
Frequency of Serious Systemic Sclerosis (SSC) Related Complications During Double-blind Period
Adverse event terms coded using MedDRA 20.1. Includes only those serious events adjudicated as SSC-related complications by an independent external committee.
Time frame: From Baseline up to Week 48
Incidence of Haematology and Hepatic Laboratory Parameters During Double-blind Period
A laboratory event occurred if the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade for a post-baseline laboratory measurement increased from baseline.
Time frame: From Baseline up to Week 48
Percentage of Participants With Change in Digital Ulcer Count During Double-blind Period
A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.
Time frame: From Baseline to Week 48
Percentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline
Incidence of anti-Tocilizumab at baseline
Time frame: Baseline
Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline up to Week 48
Incidence of anti-Tocilizumab antibodies during the study relative to the prevalence of anti-Tocilizumab antibodies at baseline. Samples that are positive for anti-TCZ in the screening assay will be further analyzed by a confirmation assay to confirm specificity. If the confirmation assay is positive, two additional tests will be performed: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.
Time frame: Double-blind period (up to Week 48)
Correlation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of Tocilizumab
Pre-specified analysis of the relationship between Anti-Tocilizumab Antibody status and safety, efficacy, and PK endpoints were not analyzed via subgroup analyses as there was only 1 patient with ADA-positive status.
Time frame: Baseline; during Weeks 8, 16, 24, 36, 48, 96, and/or at treatment discontinuation (up to 96 weeks); and 8 weeks after treatment discontinuation (up to 104 weeks overall)
Erythrocyte Sedimentation Rate (ESR), Mean, From Baseline to Week 48
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Predose up to Week 48
Erythrocyte Sedimentation Rate (ESR), Median, From Baseline to Week 48
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 48
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Interleukin (IL)-6 Level, Median, From Baseline to Week 48
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Interleukin (IL)-6 Level, Mean Change From Baseline to Week 48
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Interleukin (IL)-6 Level, Median Change From Baseline to Week 48
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, From Baseline to Week 48
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Soluble Interleukin (IL)-6 Receptor Level, Median, From Baseline to Week 48
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean Change From Baseline to Week 48
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum Soluble Interleukin (IL)-6 Receptor Level, Median Change From Baseline to Week 48
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline to Week 48
Serum C-Reactive Protein (CRP) Level, Mean, From Baseline to Week 48
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline up to Week 48
Serum C-Reactive Protein (CRP) Level, Median, From Baseline to Week 48
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline up to Week 48
Serum Tocilizumab Concentration, Mean, From Baseline to Week 48
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
Time frame: From Baseline to Week 48
Serum Tocilizumab Concentration, Median, From Baseline to Week 48
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
Time frame: From Baseline to Week 48
Correlation Between Low Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Correlation Between Low Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Correlation Between Medium Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Correlation Between Medium Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Correlation Between High Serum Tocilizumab Exposure and Mean Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Correlation Between High Serum Tocilizumab Exposure and Median Modified Rodnan Skin Score (mRSS) From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Change in Mean Modified Rodnan Skin Score (mRSS) at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Change in Median Modified Rodnan Skin Score (mRSS), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Change in Mean Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Change in Median Percent Predicted Forced Vital Capacity (ppFVC), at Low, Medium and High Serum Tocilizumab Exposure From Baseline to Week 48
In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
Time frame: From Baseline to Week 48
Summary of Adverse Events Up to Week 96
Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 21.1. NMSC = Non-Melanoma Skin Cancer
Time frame: Up to Week 96
Incidence and Severity of Adverse Events Up to Week 96
Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) severity grade: 1 = mild, 2 = moderate, 3 = severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening consequences, and 5 = death.
Time frame: Up to Week 96
Number of Participants With Adverse Events Leading to Death Up to Week 96
Time frame: Up to Week 96
Percentage of Participants With Change in Digital Ulcer Count at Week 96
A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.
Time frame: From Baseline to Week 96
Percentage of Participants With Positive Anti-Tocilizumab Assay Post-Baseline From Week 48 to 96
Reported were the percentage of participants with post-baseline treatment-induced anti-TCZ antibodies. Positive samples underwent additional analyses: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.
Time frame: Open-label period from Week 48 to 96
Erythrocyte Sedimentation Rate (ESR) Up to Week 96
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: Up to Week 96
Serum Interleukin (IL)-6 Level, Mean, From Baseline to Week 96
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: Up to Week 96
Serum Soluble Interleukin (IL)-6 Receptor Level, Mean, Up to Week 96
Serum Soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: Up to Week 96
Serum C-Reactive Protein (CRP) Level, Mean, Up to Week 96
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
Time frame: From Baseline up to Week 96
Serum Tocilizumab Concentration, Mean, Up to Week 96
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
Time frame: Up to Week 96
| Milestone | Double-Blind Placebo, Then Open Label Tocilizumab | Double-Blind Tocilizumab, Then Open Label Tocilizumab |
|---|---|---|
| Started | 106 | 104 |
| Completed | 93 | 95 |
| Not completed | 13 | 9 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Withdrawal by subject | 9 | 5 |
| Withdrew: Other | 0 | 1 |
| Milestone | Double-Blind Placebo, Then Open Label Tocilizumab | Double-Blind Tocilizumab, Then Open Label Tocilizumab |
|---|---|---|
| Started | 89 | 92 |
| Completed | 82 | 85 |
| Not completed | 7 | 7 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Withdrawal by subject | 5 | 1 |
The efficacy of TCZ vs placebo is evaluated in terms of in mean change in mRSS. Skin thickness will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period | -4.41 (-5.96 to -2.86) | -6.14 (-7.71 to -4.57) |
The proportion of participants with threshold improvements in mRSS at Week 48 relative to baseline.
| Percentage of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| ≥ 20% | 50.0 (40.01 to 59.99) | 72.1 (63.02 to 81.21) |
| ≥ 40% | 37.7 (28.04 to 47.44) | 42.3 (32.33 to 52.28) |
| ≥ 60% | 22.6 (14.20 to 31.08) | 17.3 (9.56 to 25.06) |
FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.
| Percent Predicted FVC | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change From Baseline in Percent Predicted FVC (ppFVC) During Double-blind Period | -3.910 (-4.820 to -1.620) | -0.600 (-2.380 to 0.880) |
FVC is pulmonary function test and will be conducted as per the study Pulmonary Function Manual, which is based on the American Thoracic Society/European Respiratory Society (ATS/ERS) Consensus Statement. FVC is the maximum amount of air exhaled from the lungs after taking the deepest breath possible. Patients perform three to eight exhalations into a spirometer with the highest value recorded.
| Liters of air | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change in Forced Vital Capacity (FVC) During Double-blind Period | -0.19 (-0.25 to -0.13) | -0.02 (-0.09 to 0.04) |
The Health Assessment Questionnaire Disability Index (HAQ-DI) consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The total score indicates the patient's self-assessed level of disability. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.
| Scores on a Scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score During Double-blind Period | -0.06 (-0.16 to 0.05) | -0.11 (-0.22 to -0.01) |
The Patient's Global Assessment represents the patient's overall assessment of current SSc status on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."
| mm | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change in Patient Global Assessment Score During Double-blind Period | -7.66 (-12.31 to -3.02) | -10.10 (-14.79 to -5.41) |
The Physician's Global Assessment is to be completed on the basis of examination and overall assessment of the patient. The physician's assessment of the patient's SSc status will be scored on a 100-mm horizontal visual analogue scale (VAS), ranging from 0 on the extreme left end of the scale indicating "has no effect at all" (symptom free), and 100 on the extreme right end indicating "worst possible effect."
| mm | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Change in Physician Global Assessment Score During Double-blind Period | -19.99 (-24.76 to -15.22) | -22.45 (-27.33 to -17.57) |
Time to treatment failure is defined as the time from randomization to the time of death, decline in percent-predicted FVC \> 10% relative to baseline, \> 20% increase in mRSS and an increase in mRSS of equal to or more than 5 points, or occurrence of a predefined SSc-related complication as adjudicated by the Clinical Adjudication Committee (whichever occurs first) during the 48-week double-blind treatment period. The median TTF was not estimable and is not presented for either treatment arm because of the low number of patients with events at Week 48.
| months | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Time to Treatment Failure According to mRSS, FVC, or Protocol-Specified Event During Double-blind Period | NA (48.7 to NA) | NA (NA to NA) |
Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 20.1. NMSC = Non-Melanoma Skin Cancer
| Percentage of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| At least one Adverse Event (AE) | 77.4 | 85.6 |
| Withdrawn from study due to an AE | 3.8 | 2.9 |
| Fatal AE | 2.8 | 1.0 |
| Serious Adverse Events (SAEs) | 17.0 | 12.5 |
| SAE leading to withdrawal from treatment | 3.8 | 3.8 |
| SAE leading to dose modification/interruption | 6.6 | 2.9 |
| SAE related to study drug | 6.6 | 1.0 |
| AE leading to withdrawal from treatment | 10.4 | 5.8 |
| AE leading to dose modification/interruption | 25.5 | 19.2 |
| AE related to study drug | 34.9 | 46.2 |
| Related AE leading to withdrawal from treatment | 1.9 | 1.0 |
| Related AE with dose modification/interruption | 16.0 | 11.5 |
| Infections and Infestations SAE | 6.6 | 1.9 |
| Infections and Infestations AE | 50.0 | 51.9 |
| Opportunistic Infections and Infestations AE | 0.9 | 0.0 |
| Malignancy AE | 0.9 | 1.9 |
| Malignancy AE (excluding NMSC) | 0.9 | 1.9 |
| At least one Hepatic SAE | 0.0 | 0.0 |
| At least one Stroke SAE | 0.0 | 0.0 |
| At least one Myocardial Infarction SAE | 1.9 | 0.0 |
| At least one Anaphylactic Reaction AE | 0.0 | 0.0 |
| Anaphylactic Reaction AE (Sampson's Criteria) | 0.0 | 0.0 |
| At least one Gastrointestinal Perforation SAE | 0.0 | 0.0 |
| At least one Bleeding SAE | 0.9 | 0.0 |
| At least one Demyelinating SAE | 0.0 | 0.0 |
Adverse events listed according to MedDRA version 20.1 preferred terms and severity grade.
| Number of participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| NASOPHARYNGITIS GRADE 1 | 6 | 10 |
| NASOPHARYNGITIS GRADE 2 | 2 | 3 |
| URINARY TRACT INFECTION GRADE 1 | 5 | 1 |
| URINARY TRACT INFECTION GRADE 2 | 5 | 3 |
| URINARY TRACT INFECTION GRADE 3 | 0 | 1 |
| GASTROENTERITIS GRADE 1 | 0 | 2 |
| GASTROENTERITIS GRADE 2 | 2 | 4 |
| HERPES ZOSTER GRADE 2 | 5 | 0 |
| HERPES ZOSTER GRADE 3 | 0 | 2 |
| PHARYNGITIS GRADE 1 | 2 | 1 |
| PHARYNGITIS GRADE 2 | 2 | 2 |
| INFECTED SKIN ULCER GRADE 1 | 0 | 1 |
| INFECTED SKIN ULCER GRADE 2 | 1 | 3 |
| INFECTED SKIN ULCER GRADE 3 | 1 | 0 |
| BRONCHITIS GRADE 1 | 1 | 1 |
| BRONCHITIS GRADE 2 | 1 | 2 |
| INFLUENZA GRADE 1 | 1 | 2 |
| INFLUENZA GRADE 2 | 1 | 1 |
| LATENT TUBERCULOSIS GRADE 1 | 1 | 2 |
| LATENT TUBERCULOSIS GRADE 2 | 0 | 2 |
| PNEUMONIA GRADE 2 | 1 | 1 |
| PNEUMONIA GRADE 3 | 3 | 0 |
| RESPIRATORY TRACT INFECTION GRADE 1 | 1 | 1 |
| RESPIRATORY TRACT INFECTION GRADE 2 | 0 | 1 |
| RESPIRATORY TRACT INFECTION GRADE 3 | 1 | 0 |
| SINUSITIS GRADE 1 | 1 | 0 |
| SINUSITIS GRADE 2 | 1 | 1 |
| SINUSITIS GRADE 3 | 0 | 1 |
| WOUND INFECTION GRADE 1 | 0 | 2 |
| WOUND INFECTION GRADE 2 | 1 | 0 |
| WOUND INFECTION GRADE 3 | 1 | 0 |
| CYSTITIS GRADE 1 | 0 | 1 |
| CYSTITIS GRADE 2 | 0 | 2 |
| LOCALISED INFECTION GRADE 1 | 1 | 0 |
| LOCALISED INFECTION GRADE 2 | 2 | 0 |
| ORAL CANDIDIASIS GRADE 1 | 2 | 1 |
| PARONYCHIA GRADE 2 | 2 | 0 |
| PARONYCHIA GRADE 3 | 1 | 0 |
| VULVOVAGINAL MYCOTIC INFECTION GRADE 2 | 2 | 1 |
| CANDIDA INFECTION GRADE 1 | 1 | 0 |
| CANDIDA INFECTION GRADE 2 | 1 | 0 |
| FOLLICULITIS GRADE 1 | 0 | 1 |
| FOLLICULITIS GRADE 2 | 1 | 0 |
| GASTROINTESTINAL INFECTION GRADE 2 | 2 | 0 |
| HORDEOLUM GRADE 1 | 0 | 2 |
| RHINITIS GRADE 2 | 1 | 1 |
| SOFT TISSUE INFECTION GRADE 2 | 1 | 0 |
| SOFT TISSUE INFECTION GRADE 4 | 1 | 0 |
| TINEA PEDIS GRADE 1 | 0 | 1 |
| TINEA PEDIS GRADE 2 | 0 | 1 |
| VIRAL UPPER RESPIRATORY TRACT INFECTION GRADE 1 | 1 | 0 |
| VIRAL UPPER RESPIRATORY TRACT INFECTION GRADE 2 | 1 | 0 |
| ABSCESS JAW GRADE 3 | 1 | 0 |
| ACUTE SINUSITIS GRADE 2 | 1 | 0 |
| BACTERAEMIA GRADE 2 | 1 | 0 |
| BODY TINEA GRADE 1 | 1 | 0 |
| CAMPYLOBACTER GASTROENTERITIS GRADE 1 | 0 | 1 |
| GASTROENTERITIS VIRAL GRADE 2 | 1 | 0 |
| GASTROINTESTINAL BACTERIAL OVERGROWTH GRADE 2 | 1 | 0 |
| GASTROINTESTINAL VIRAL INFECTION GRADE 1 | 1 | 0 |
| GINGIVITIS GRADE 2 | 1 | 0 |
| HERPES SIMPLEX GRADE 1 | 1 | 0 |
| INFECTIOUS MONONUCLEOSIS GRADE 1 | 1 | 0 |
| LARYNGITIS GRADE 1 | 1 | 0 |
| LICE INFESTATION GRADE 3 | 0 | 1 |
| OESOPHAGEAL CANDIDIASIS GRADE 2 | 1 | 0 |
| ORAL HERPES GRADE 2 | 1 | 0 |
| OSTEOMYELITIS GRADE 3 | 0 | 1 |
| PELVIC INFLAMMATORY DISEASE GRADE 3 | 0 | 1 |
| PERIODONTITIS GRADE 2 | 1 | 0 |
| PERIORBITAL CELLULITIS GRADE 1 | 0 | 1 |
| PHARYNGITIS STREPTOCOCCAL GRADE 1 | 1 | 0 |
| PULMONARY TUBERCULOSIS GRADE 3 | 0 | 1 |
| PULPITIS DENTAL GRADE 1 | 0 | 1 |
| PYELONEPHRITIS CHRONIC GRADE 3 | 1 | 0 |
| RASH PUSTULAR GRADE 1 | 0 | 1 |
| RESPIRATORY TRACT INFECTION BACTERIAL GRADE 2 | 0 | 1 |
| SEPSIS GRADE 3 | 1 | 0 |
| SKIN BACTERIAL INFECTION GRADE 2 | 1 | 0 |
| TONSILLITIS GRADE 2 | 0 | 1 |
| TOOTH INFECTION GRADE 3 | 1 | 0 |
| VIRAL INFECTION GRADE 1 | 0 | 1 |
| WOUND INFECTION STAPHYLOCOCCAL GRADE 1 | 0 | 1 |
| ARTHRALGIA GRADE 1 | 3 | 8 |
| ARTHRALGIA GRADE 2 | 8 | 3 |
| ARTHRALGIA GRADE 3 | 1 | 0 |
| BACK PAIN GRADE 1 | 1 | 1 |
| BACK PAIN GRADE 2 | 4 | 1 |
| MUSCLE SPASMS GRADE 1 | 1 | 2 |
| MUSCLE SPASMS GRADE 2 | 1 | 1 |
| MUSCLE SPASMS GRADE 3 | 1 | 0 |
| PAIN IN EXTREMITY GRADE 1 | 2 | 2 |
| PAIN IN EXTREMITY GRADE 2 | 0 | 1 |
| PAIN IN EXTREMITY GRADE 3 | 1 | 0 |
| MUSCULOSKELETAL PAIN GRADE 1 | 1 | 0 |
| MUSCULOSKELETAL PAIN GRADE 2 | 4 | 0 |
| BURSITIS GRADE 1 | 3 | 0 |
| BURSITIS GRADE 2 | 0 | 1 |
| MYALGIA GRADE 1 | 1 | 0 |
| MYALGIA GRADE 2 | 3 | 0 |
| ARTHRITIS GRADE 2 | 2 | 1 |
| INTERVERTEBRAL DISC PROTRUSION GRADE 1 | 1 | 1 |
| INTERVERTEBRAL DISC PROTRUSION GRADE 2 | 0 | 1 |
| MYOSITIS GRADE 1 | 1 | 0 |
| MYOSITIS GRADE 2 | 1 | 1 |
| OSTEOCHONDROSIS GRADE 1 | 1 | 2 |
| FOOT DEFORMITY GRADE 1 | 1 | 1 |
| SCLERODERMA GRADE 2 | 0 | 1 |
| SCLERODERMA GRADE 4 | 1 | 0 |
| SJOGREN'S SYNDROME GRADE 1 | 1 | 0 |
| SJOGREN'S SYNDROME GRADE 2 | 1 | 0 |
| SPINAL OSTEOARTHRITIS GRADE 1 | 0 | 1 |
| SPINAL OSTEOARTHRITIS GRADE 2 | 1 | 0 |
| EXTREMITY CONTRACTURE GRADE 1 | 1 | 0 |
| FIBROMYALGIA GRADE 1 | 1 | 0 |
| FLANK PAIN GRADE 1 | 0 | 1 |
| JOINT STIFFNESS GRADE 1 | 0 | 1 |
| JOINT SWELLING GRADE 2 | 1 | 0 |
| MUSCLE CONTRACTURE GRADE 1 | 0 | 1 |
| MUSCLE FATIGUE GRADE 1 | 1 | 0 |
| MUSCULAR WEAKNESS GRADE 2 | 0 | 1 |
| MUSCULOSKELETAL CHEST PAIN GRADE 1 | 1 | 0 |
| MYOPATHY GRADE 1 | 1 | 0 |
| NECK PAIN GRADE 2 | 1 | 0 |
| OSTEOPENIA GRADE 1 | 0 | 1 |
| OSTEOPOROSIS GRADE 2 | 0 | 1 |
| OSTEOPOROTIC FRACTURE GRADE 2 | 1 | 0 |
| PAIN IN JAW GRADE 1 | 1 | 0 |
| POLYARTHRITIS GRADE 2 | 1 | 0 |
| TENOSYNOVITIS GRADE 2 | 0 | 1 |
| TENOSYNOVITIS STENOSANS GRADE 1 | 1 | 0 |
| SKIN ULCER GRADE 1 | 5 | 8 |
| SKIN ULCER GRADE 2 | 7 | 5 |
| SKIN ULCER GRADE 3 | 0 | 2 |
| PRURITUS GRADE 1 | 2 | 1 |
| PRURITUS GRADE 2 | 2 | 5 |
| RASH GRADE 1 | 4 | 2 |
| RASH GRADE 2 | 3 | 0 |
| ERYTHEMA GRADE 1 | 1 | 4 |
| ECZEMA GRADE 1 | 0 | 2 |
| ECZEMA GRADE 2 | 2 | 0 |
| ROSACEA GRADE 1 | 0 | 1 |
| ROSACEA GRADE 2 | 1 | 1 |
| SKIN TIGHTNESS GRADE 1 | 2 | 1 |
| DERMATITIS CONTACT GRADE 2 | 1 | 1 |
| INGROWING NAIL GRADE 1 | 0 | 1 |
| INGROWING NAIL GRADE 2 | 1 | 0 |
| MACULE GRADE 1 | 1 | 1 |
| NIGHT SWEATS GRADE 1 | 2 | 0 |
| SKIN DISCOLOURATION GRADE 1 | 0 | 2 |
| SKIN FISSURES GRADE 1 | 0 | 2 |
| SKIN HYPERTROPHY GRADE 1 | 0 | 2 |
| SKIN INDURATION GRADE 1 | 2 | 0 |
| URTICARIA GRADE 1 | 0 | 1 |
| URTICARIA GRADE 2 | 1 | 0 |
| ALOPECIA GRADE 1 | 0 | 1 |
| BLISTER GRADE 2 | 0 | 1 |
| CHLOASMA GRADE 1 | 1 | 0 |
| COLD SWEAT GRADE 1 | 1 | 0 |
| DECUBITUS ULCER GRADE 2 | 0 | 1 |
| DERMATITIS ACNEIFORM GRADE 1 | 0 | 1 |
| DERMATITIS ATOPIC GRADE 1 | 0 | 1 |
| DIGITAL PITTING SCAR GRADE 4 | 1 | 0 |
| DRY SKIN GRADE 1 | 0 | 1 |
| ECCHYMOSIS GRADE 3 | 1 | 0 |
| EXCESSIVE GRANULATION TISSUE GRADE 3 | 0 | 1 |
| HYPERTRICHOSIS GRADE 1 | 1 | 0 |
| ONYCHOLYSIS GRADE 1 | 1 | 0 |
| PAIN OF SKIN GRADE 1 | 1 | 0 |
| PAPULE GRADE 1 | 1 | 0 |
| RASH ERYTHEMATOUS GRADE 1 | 0 | 1 |
| RASH MACULO-PAPULAR GRADE 3 | 0 | 1 |
| SKIN DEPIGMENTATION GRADE 1 | 1 | 0 |
| SKIN FIBROSIS GRADE 2 | 1 | 0 |
| SKIN HYPOPIGMENTATION GRADE 1 | 1 | 0 |
| SKIN OEDEMA GRADE 1 | 1 | 0 |
| VITILIGO GRADE 2 | 1 | 0 |
| DIARRHOEA GRADE 1 | 5 | 6 |
| DIARRHOEA GRADE 2 | 3 | 0 |
| GASTROOESOPHAGEAL REFLUX DISEASE GRADE 1 | 3 | 3 |
| GASTROOESOPHAGEAL REFLUX DISEASE GRADE 2 | 2 | 1 |
| NAUSEA GRADE 1 | 5 | 3 |
| NAUSEA GRADE 2 | 1 | 0 |
| ABDOMINAL PAIN GRADE 1 | 3 | 1 |
| ABDOMINAL PAIN GRADE 2 | 1 | 0 |
| ABDOMINAL PAIN GRADE 3 | 1 | 0 |
| CONSTIPATION GRADE 1 | 2 | 2 |
| CONSTIPATION GRADE 2 | 2 | 0 |
| DYSPEPSIA GRADE 1 | 1 | 2 |
| DYSPEPSIA GRADE 2 | 1 | 1 |
| DYSPHAGIA GRADE 1 | 2 | 2 |
| DYSPHAGIA GRADE 2 | 0 | 1 |
| STOMATITIS GRADE 1 | 1 | 1 |
| STOMATITIS GRADE 2 | 1 | 0 |
| VOMITING GRADE 1 | 1 | 1 |
| VOMITING GRADE 3 | 0 | 1 |
| ABDOMINAL DISCOMFORT GRADE 1 | 0 | 1 |
| ABDOMINAL DISCOMFORT GRADE 2 | 1 | 0 |
| ABDOMINAL DISTENSION GRADE 1 | 1 | 0 |
| ABDOMINAL DISTENSION GRADE 2 | 1 | 0 |
| ABDOMINAL PAIN UPPER GRADE 1 | 1 | 1 |
| DENTAL CARIES GRADE 2 | 1 | 1 |
| FAECES SOFT GRADE 1 | 1 | 1 |
| HAEMORRHOIDS GRADE 1 | 1 | 0 |
| HAEMORRHOIDS GRADE 2 | 1 | 0 |
| TOOTHACHE GRADE 2 | 2 | 0 |
| ANAL HAEMORRHAGE GRADE 2 | 1 | 0 |
| CHRONIC GASTRITIS GRADE 1 | 1 | 0 |
| DIVERTICULUM INTESTINAL GRADE 1 | 0 | 1 |
| DRY MOUTH GRADE 2 | 0 | 1 |
| DUODENITIS GRADE 1 | 0 | 1 |
| GASTRIC DISORDER GRADE 1 | 0 | 1 |
| GASTRIC POLYPS GRADE 1 | 1 | 0 |
| GASTRITIS GRADE 2 | 1 | 0 |
| HAEMATOCHEZIA GRADE 1 | 0 | 1 |
| ILEUS PARALYTIC GRADE 3 | 1 | 0 |
| LOOSE TOOTH GRADE 1 | 0 | 1 |
| OESOPHAGEAL DISORDER GRADE 1 | 1 | 0 |
| OESOPHAGEAL HYPOMOTILITY GRADE 2 | 0 | 1 |
| PERIODONTAL DISEASE GRADE 2 | 1 | 0 |
| PNEUMATOSIS INTESTINALIS GRADE 2 | 0 | 1 |
| RANULA GRADE 1 | 0 | 1 |
| SWOLLEN TONGUE GRADE 2 | 0 | 1 |
| FATIGUE GRADE 1 | 3 | 7 |
| FATIGUE GRADE 2 | 4 | 1 |
| OEDEMA PERIPHERAL GRADE 1 | 2 | 1 |
| OEDEMA PERIPHERAL GRADE 2 | 1 | 0 |
| ASTHENIA GRADE 1 | 2 | 0 |
| ASTHENIA GRADE 3 | 1 | 0 |
| CALCINOSIS GRADE 1 | 1 | 2 |
| INJECTION SITE ERYTHEMA GRADE 1 | 0 | 1 |
| INJECTION SITE ERYTHEMA GRADE 2 | 0 | 1 |
| INJECTION SITE ERYTHEMA GRADE 3 | 0 | 1 |
| INJECTION SITE REACTION GRADE 1 | 0 | 1 |
| INJECTION SITE REACTION GRADE 2 | 1 | 1 |
| PAIN GRADE 2 | 1 | 0 |
| PAIN GRADE 3 | 0 | 1 |
| PAIN GRADE 4 | 1 | 0 |
| CHEST PAIN GRADE 1 | 2 | 0 |
| CYST GRADE 1 | 1 | 0 |
| CYST GRADE 2 | 1 | 0 |
| INFLUENZA LIKE ILLNESS GRADE 1 | 1 | 1 |
| DEATH GRADE 5 | 0 | 1 |
| FEELING HOT GRADE 1 | 0 | 1 |
| GRANULOMA GRADE 1 | 1 | 0 |
| INJECTION SITE EXTRAVASATION GRADE 1 | 0 | 1 |
| INJECTION SITE INDURATION GRADE 2 | 0 | 1 |
| INJECTION SITE PRURITUS GRADE 2 | 0 | 1 |
| MALAISE GRADE 1 | 0 | 1 |
| NODULE GRADE 1 | 1 | 0 |
| PERIPHERAL SWELLING GRADE 2 | 1 | 0 |
| PYREXIA GRADE 1 | 1 | 0 |
| SENSATION OF FOREIGN BODY GRADE 1 | 0 | 1 |
| VESSEL PUNCTURE SITE PAIN GRADE 1 | 0 | 1 |
| WEIGHT DECREASED GRADE 1 | 3 | 1 |
| WEIGHT DECREASED GRADE 2 | 3 | 2 |
| ALANINE AMINOTRANSFERASE INCREASED GRADE 1 | 0 | 2 |
| ALANINE AMINOTRANSFERASE INCREASED GRADE 2 | 2 | 0 |
| ALANINE AMINOTRANSFERASE INCREASED GRADE 3 | 0 | 2 |
| ASPARTATE AMINOTRANSFERASE INCREASED GRADE 1 | 0 | 2 |
| ASPARTATE AMINOTRANSFERASE INCREASED GRADE 2 | 2 | 0 |
| ASPARTATE AMINOTRANSFERASE INCREASED GRADE 3 | 0 | 1 |
| HEPATIC ENZYME INCREASED GRADE 1 | 1 | 0 |
| HEPATIC ENZYME INCREASED GRADE 2 | 1 | 1 |
| HEPATIC ENZYME INCREASED GRADE 3 | 1 | 0 |
| WEIGHT INCREASED GRADE 1 | 2 | 2 |
| TRANSAMINASES INCREASED GRADE 1 | 0 | 1 |
| TRANSAMINASES INCREASED GRADE 2 | 2 | 0 |
| BLOOD CHOLESTEROL INCREASED GRADE 1 | 0 | 1 |
| BLOOD CHOLESTEROL INCREASED GRADE 2 | 0 | 1 |
| UPPER RESPIRATORY TRACT INFECTION GRADE 1 | 4 | 7 |
| UPPER RESPIRATORY TRACT INFECTION GRADE 2 | 7 | 4 |
| UPPER RESPIRATORY TRACT INFECTION GRADE 3 | 0 | 1 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED GRADE 1 | 0 | 1 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED GRADE 2 | 0 | 1 |
| BLOOD BILIRUBIN INCREASED GRADE 1 | 0 | 1 |
| BLOOD URINE PRESENT GRADE 2 | 1 | 0 |
| CAROTID INTIMA-MEDIA THICKNESS INCREASED GRADE 1 | 1 | 0 |
| COMPUTERISED TOMOGRAM THORAX ABNORMAL GRADE 2 | 1 | 0 |
| HAEMOGLOBIN DECREASED GRADE 2 | 1 | 0 |
| LIVER FUNCTION TEST ABNORMAL GRADE 2 | 0 | 1 |
| LOW DENSITY LIPOPROTEIN INCREASED GRADE 2 | 0 | 1 |
| PROTEIN URINE PRESENT GRADE 2 | 1 | 0 |
| TRANSFERRIN SATURATION INCREASED GRADE 1 | 0 | 1 |
| TUBERCULIN TEST POSITIVE GRADE 2 | 1 | 0 |
| URINE BILIRUBIN INCREASED GRADE 2 | 1 | 0 |
| UROBILINOGEN URINE INCREASED GRADE 2 | 1 | 0 |
| WHITE BLOOD CELLS URINE POSITIVE GRADE 1 | 1 | 0 |
| COUGH GRADE 1 | 3 | 1 |
| COUGH GRADE 2 | 2 | 2 |
| INTERSTITIAL LUNG DISEASE GRADE 1 | 3 | 0 |
| INTERSTITIAL LUNG DISEASE GRADE 2 | 5 | 0 |
| DYSPNOEA GRADE 1 | 1 | 1 |
| DYSPNOEA GRADE 2 | 2 | 2 |
| EPISTAXIS GRADE 1 | 3 | 1 |
| EPISTAXIS GRADE 2 | 0 | 1 |
| DYSPNOEA EXERTIONAL GRADE 1 | 1 | 0 |
| DYSPNOEA EXERTIONAL GRADE 2 | 1 | 0 |
| DYSPNOEA EXERTIONAL GRADE 3 | 1 | 0 |
| OROPHARYNGEAL PAIN GRADE 1 | 1 | 1 |
| OROPHARYNGEAL PAIN GRADE 2 | 1 | 0 |
| PRODUCTIVE COUGH GRADE 1 | 2 | 0 |
| DYSPHONIA GRADE 1 | 1 | 0 |
| HAEMOPTYSIS GRADE 1 | 0 | 1 |
| PAINFUL RESPIRATION GRADE 1 | 1 | 0 |
| PLEURAL EFFUSION GRADE 4 | 1 | 0 |
| PNEUMONITIS GRADE 2 | 1 | 0 |
| RHINITIS ALLERGIC GRADE 1 | 1 | 0 |
| RHINORRHOEA GRADE 1 | 1 | 0 |
| HEADACHE GRADE 1 | 3 | 3 |
| HEADACHE GRADE 2 | 4 | 0 |
| DIZZINESS GRADE 1 | 2 | 2 |
| DIZZINESS GRADE 2 | 1 | 1 |
| NEUROPATHY PERIPHERAL GRADE 2 | 2 | 0 |
| POST HERPETIC NEURALGIA GRADE 2 | 2 | 0 |
| CARPAL TUNNEL SYNDROME GRADE 1 | 1 | 0 |
| DYSGEUSIA GRADE 1 | 1 | 0 |
| HYPOAESTHESIA GRADE 1 | 1 | 0 |
| HYPOKINESIA GRADE 3 | 0 | 1 |
| MEMORY IMPAIRMENT GRADE 1 | 0 | 1 |
| NERVE COMPRESSION GRADE 1 | 1 | 0 |
| NEURALGIA GRADE 1 | 1 | 0 |
| PARAESTHESIA GRADE 1 | 0 | 1 |
| PARKINSONISM GRADE 2 | 1 | 0 |
| PRESYNCOPE GRADE 1 | 0 | 1 |
| RADICULAR PAIN GRADE 1 | 0 | 1 |
| SENSORY LOSS GRADE 1 | 1 | 0 |
| SOMNOLENCE GRADE 1 | 0 | 1 |
| LIMB INJURY GRADE 1 | 2 | 1 |
| LIMB INJURY GRADE 2 | 2 | 0 |
| LIMB INJURY GRADE 3 | 0 | 1 |
| FALL GRADE 1 | 0 | 1 |
| FALL GRADE 2 | 0 | 2 |
| EAR INJURY GRADE 1 | 0 | 2 |
| LACERATION GRADE 1 | 1 | 0 |
| LACERATION GRADE 2 | 1 | 0 |
| SCAR GRADE 1 | 0 | 1 |
| SCAR GRADE 2 | 1 | 0 |
| WOUND GRADE 1 | 0 | 1 |
| WOUND GRADE 2 | 1 | 0 |
| ANIMAL BITE GRADE 2 | 0 | 1 |
| ANKLE FRACTURE GRADE 1 | 0 | 1 |
| ARTHROPOD STING GRADE 1 | 1 | 0 |
| CONTUSION GRADE 1 | 0 | 1 |
| CRANIOCEREBRAL INJURY GRADE 2 | 1 | 0 |
| EXCORIATION GRADE 1 | 0 | 1 |
| FACE INJURY GRADE 1 | 0 | 1 |
| INJURY CORNEAL GRADE 2 | 1 | 0 |
| JOINT INJURY GRADE 3 | 0 | 1 |
| LIGAMENT SPRAIN GRADE 1 | 0 | 1 |
| LIMB TRAUMATIC AMPUTATION GRADE 3 | 0 | 1 |
| MENISCUS INJURY GRADE 3 | 0 | 1 |
| MUSCLE RUPTURE GRADE 2 | 0 | 1 |
| MUSCLE STRAIN GRADE 2 | 1 | 0 |
| ROAD TRAFFIC ACCIDENT GRADE 1 | 0 | 1 |
| SKIN ABRASION GRADE 1 | 1 | 0 |
| SPINAL COMPRESSION FRACTURE GRADE 2 | 1 | 0 |
| THERMAL BURN GRADE 1 | 0 | 1 |
| ANAEMIA GRADE 1 | 3 | 0 |
| ANAEMIA GRADE 2 | 2 | 1 |
| ANAEMIA GRADE 3 | 1 | 0 |
| IRON DEFICIENCY ANAEMIA GRADE 1 | 1 | 0 |
| IRON DEFICIENCY ANAEMIA GRADE 2 | 1 | 0 |
| IRON DEFICIENCY ANAEMIA GRADE 3 | 0 | 1 |
| LYMPHOPENIA GRADE 2 | 0 | 1 |
| LYMPHOPENIA GRADE 3 | 1 | 0 |
| NEUTROPENIA GRADE 2 | 0 | 1 |
| NEUTROPENIA GRADE 3 | 1 | 0 |
| ANAEMIA MEGALOBLASTIC GRADE 2 | 1 | 0 |
| EOSINOPHILIA GRADE 1 | 0 | 1 |
| LEUKOCYTOSIS GRADE 1 | 1 | 0 |
| LEUKOPENIA GRADE 2 | 0 | 1 |
| LYMPHADENOPATHY MEDIASTINAL GRADE 2 | 1 | 0 |
| MICROANGIOPATHIC HAEMOLYTIC ANAEMIA GRADE 2 | 0 | 1 |
| MICROCYTIC ANAEMIA GRADE 1 | 0 | 1 |
| THROMBOCYTOPENIA GRADE 1 | 0 | 1 |
| DECREASED APPETITE GRADE 1 | 4 | 1 |
| DYSLIPIDAEMIA GRADE 1 | 0 | 2 |
| DYSLIPIDAEMIA GRADE 2 | 1 | 1 |
| HYPERCHOLESTEROLAEMIA GRADE 1 | 0 | 1 |
| HYPERCHOLESTEROLAEMIA GRADE 2 | 0 | 1 |
| HYPERTRIGLYCERIDAEMIA GRADE 2 | 1 | 1 |
| DIABETES MELLITUS GRADE 2 | 1 | 0 |
| DIABETIC KETOACIDOSIS GRADE 4 | 1 | 0 |
| DIABETIC METABOLIC DECOMPENSATION GRADE 1 | 0 | 1 |
| FOLATE DEFICIENCY GRADE 1 | 0 | 1 |
| GOUT GRADE 2 | 1 | 0 |
| HYPERGLYCAEMIA GRADE 3 | 1 | 0 |
| HYPERLIPIDAEMIA GRADE 1 | 0 | 1 |
| HYPONATRAEMIA GRADE 1 | 1 | 0 |
| IRON DEFICIENCY GRADE 2 | 1 | 0 |
| OBESITY GRADE 1 | 0 | 1 |
| WEIGHT FLUCTUATION GRADE 1 | 1 | 0 |
| PALPITATIONS GRADE 1 | 4 | 1 |
| PALPITATIONS GRADE 3 | 0 | 1 |
| BUNDLE BRANCH BLOCK RIGHT GRADE 1 | 1 | 0 |
| BUNDLE BRANCH BLOCK RIGHT GRADE 2 | 0 | 1 |
| PERICARDIAL EFFUSION GRADE 1 | 1 | 0 |
| PERICARDIAL EFFUSION GRADE 2 | 1 | 0 |
| ACUTE MYOCARDIAL INFARCTION GRADE 3 | 1 | 0 |
| ANGINA PECTORIS GRADE 3 | 0 | 1 |
| ATRIAL FIBRILLATION GRADE 3 | 1 | 0 |
| ATRIAL TACHYCARDIA GRADE 2 | 1 | 0 |
| BRADYCARDIA GRADE 1 | 0 | 1 |
| CARDIAC FAILURE GRADE 3 | 0 | 1 |
| CARDIAC FAILURE CHRONIC GRADE 5 | 1 | 0 |
| MICROVASCULAR CORONARY ARTERY DISEASE GRADE 2 | 1 | 0 |
| MYOCARDIAL INFARCTION GRADE 5 | 1 | 0 |
| MYOCARDITIS GRADE 5 | 1 | 0 |
| PERICARDITIS GRADE 2 | 1 | 0 |
| SUPRAVENTRICULAR EXTRASYSTOLES GRADE 1 | 1 | 0 |
| TACHYCARDIA GRADE 1 | 1 | 0 |
| ANXIETY GRADE 1 | 2 | 1 |
| ANXIETY GRADE 2 | 1 | 0 |
| INSOMNIA GRADE 1 | 2 | 1 |
| STRESS GRADE 1 | 1 | 1 |
| ADJUSTMENT DISORDER GRADE 3 | 1 | 0 |
| DEPRESSED MOOD GRADE 3 | 0 | 1 |
| DEPRESSION GRADE 1 | 0 | 1 |
| GENERALISED ANXIETY DISORDER GRADE 2 | 1 | 0 |
| SLEEP DISORDER GRADE 1 | 1 | 0 |
| CHALAZION GRADE 1 | 0 | 2 |
| GLAUCOMA GRADE 1 | 0 | 1 |
| GLAUCOMA GRADE 3 | 1 | 0 |
| BLEPHARITIS GRADE 2 | 0 | 1 |
| CATARACT GRADE 3 | 1 | 0 |
| CONJUNCTIVAL HAEMORRHAGE GRADE 1 | 1 | 0 |
| DRY EYE GRADE 1 | 0 | 1 |
| EYELID OEDEMA GRADE 1 | 0 | 1 |
| KERATITIS GRADE 2 | 0 | 1 |
| VISUAL IMPAIRMENT GRADE 1 | 0 | 1 |
| RAYNAUD'S PHENOMENON GRADE 1 | 1 | 3 |
| RAYNAUD'S PHENOMENON GRADE 2 | 1 | 0 |
| BLOOD PRESSURE FLUCTUATION GRADE 1 | 0 | 1 |
| HYPERTENSION GRADE 2 | 0 | 1 |
| HYPOTENSION GRADE 2 | 1 | 0 |
| PERIPHERAL ISCHAEMIA GRADE 2 | 0 | 1 |
| THROMBOPHLEBITIS GRADE 2 | 0 | 1 |
| VASCULITIS GRADE 2 | 1 | 0 |
| ACUTE KIDNEY INJURY GRADE 3 | 1 | 0 |
| DYSURIA GRADE 1 | 1 | 0 |
| HAEMATURIA GRADE 1 | 1 | 0 |
| NEPHROLITHIASIS GRADE 3 | 0 | 1 |
| RENAL COLIC GRADE 2 | 0 | 1 |
| RENAL CYST GRADE 1 | 1 | 0 |
| RENAL PAIN GRADE 2 | 1 | 0 |
| SCLERODERMA RENAL CRISIS GRADE 3 | 0 | 1 |
| AMENORRHOEA GRADE 1 | 0 | 1 |
| BREAST CYST GRADE 1 | 1 | 0 |
| CERVICAL POLYP GRADE 1 | 0 | 1 |
| ERECTILE DYSFUNCTION GRADE 2 | 1 | 0 |
| GENITAL RASH GRADE 2 | 1 | 0 |
| MENSTRUATION IRREGULAR GRADE 1 | 1 | 0 |
| OVARIAN CYST RUPTURED GRADE 2 | 1 | 0 |
| PENILE PAIN GRADE 1 | 1 | 0 |
| B-CELL LYMPHOMA GRADE 3 | 0 | 1 |
| BENIGN BONE NEOPLASM GRADE 3 | 1 | 0 |
| BENIGN LUNG NEOPLASM GRADE 1 | 0 | 1 |
| BREAST CANCER GRADE 3 | 0 | 1 |
| LUNG ADENOCARCINOMA GRADE 4 | 1 | 0 |
| SKIN PAPILLOMA GRADE 2 | 0 | 1 |
| FOOD ALLERGY GRADE 2 | 0 | 1 |
| HYPERSENSITIVITY GRADE 1 | 0 | 1 |
| TYPE I HYPERSENSITIVITY GRADE 2 | 0 | 1 |
| MICROSTOMIA GRADE 1 | 1 | 0 |
| MICROSTOMIA GRADE 2 | 0 | 1 |
| PRESBYACUSIS GRADE 1 | 0 | 1 |
| VERTIGO GRADE 1 | 1 | 0 |
| HYPOTHYROIDISM GRADE 1 | 0 | 1 |
| THYROID MASS GRADE 1 | 1 | 0 |
| HEPATIC STEATOSIS GRADE 1 | 0 | 1 |
| NEEDLE ISSUE GRADE 1 | 0 | 1 |
| CATARACT OPERATION GRADE 3 | 1 | 0 |
Reason of death is coded using MedDRA 20.1
| Number of participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| CARDIAC FAILURE CHRONIC | 1 | 0 |
| MYOCARDITIS | 1 | 0 |
| MYOCARDIAL INFARCTION | 1 | 0 |
| DEATH | 0 | 1 |
Adverse event terms coded using MedDRA 20.1. Includes only those serious events adjudicated as SSC-related complications by an independent external committee.
| Number of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| CARDIAC FAILURE | 0 | 1 |
| CARDIAC FAILURE CHRONIC | 1 | 0 |
| MICROVASCULAR CORONARY ARTERY DISEASE | 1 | 0 |
| MYOCARDITIS | 1 | 0 |
| INFECTED SKIN ULCER | 1 | 0 |
| OSTEOMYELITIS | 0 | 1 |
| WOUND INFECTION | 0 | 1 |
| ILEUS PARALYTIC | 1 | 0 |
| PAIN | 1 | 0 |
| WEIGHT DECREASED | 0 | 1 |
| SCLERODERMA | 1 | 0 |
| HYPOKINESIA | 0 | 1 |
| ADJUSTMENT DISORDER | 1 | 0 |
| SCLERODERMA RENAL CRISIS | 0 | 1 |
| DIGITAL PITTING SCAR | 1 | 0 |
A laboratory event occurred if the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade for a post-baseline laboratory measurement increased from baseline.
| Number of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| High Alkaline Phosphatase | 7 | 1 |
| High SGPT/ALT | 17 | 32 |
| High SGOT/AST | 17 | 24 |
| Low Neutrophils, Segmented, Abs | 2 | 27 |
| Low Platelet | 0 | 9 |
| High Bilirubin | 1 | 13 |
A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.
| Percentage of participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| No change | 85.4 | 87.2 |
| Increase by 1 | 3.4 | 5.3 |
| Increase by 2 | 1.1 | 1.1 |
| Increase by 3 | 0 | 0 |
| Increase by 4 | 0 | 0 |
| Increase by >4 | 1.1 | 0 |
| Decrease by 1 | 3.4 | 4.3 |
| Decrease by 2 | 3.4 | 0 |
| Decrease by 3 | 0 | 1.1 |
| Decrease by 4 | 1.1 | 0 |
| Decrease by >4 | 0 | 0 |
| Baseline missing | 1.1 | 1.1 |
Incidence of anti-Tocilizumab at baseline
| Percentage of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Percentage of Participants With Positive Anti-Tocilizumab Assay Result at Baseline | 5.9 | 2.9 |
Incidence of anti-Tocilizumab antibodies during the study relative to the prevalence of anti-Tocilizumab antibodies at baseline. Samples that are positive for anti-TCZ in the screening assay will be further analyzed by a confirmation assay to confirm specificity. If the confirmation assay is positive, two additional tests will be performed: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.
| Percentage of Participants | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Positive Anti-TCZ Assay | 0.0 | 2.9 |
| Positive Confirmation Assay | 0.0 | 1.0 |
| Positive Neutralizing Assay | 0.0 | 1.0 |
| Positive IgE Assay | 0.0 | 0.0 |
Pre-specified analysis of the relationship between Anti-Tocilizumab Antibody status and safety, efficacy, and PK endpoints were not analyzed via subgroup analyses as there was only 1 patient with ADA-positive status.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Correlation Between Anti-Tocilizumab Antibody Status and Outcome Measures Pertaining to the Efficacy, Safety, and Pharmacokinetics of Tocilizumab | NA (NA to NA) | NA (NA to NA) |
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
| mm/hr | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 34.72 ± 18.49 | 34.83 ± 16.29 |
| Week 4 | 31.38 ± 19.00 | 14.29 ± 12.98 |
| Week 24 | 28.49 ± 20.86 | 8.46 ± 8.63 |
| Week 48 | 26.59 ± 18.62 | 10.82 ± 15.53 |
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
| mm/hr | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 33.0 (23.00 to 43.00) | 33.50 (26.00 to 42.00) |
| Week 4 | 30.00 (16.50 to 39.50) | 9.50 (4.00 to 23.00) |
| Week 24 | 25.00 (12.00 to 36.00) | 5.00 (3.00 to 8.00) |
| Week 48 | 22.50 (14.00 to 31.50) | 5.50 (3.00 to 12.00) |
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
| pg/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 11.83 ± 19.74 | 13.88 ± 43.77 |
| Week 4 | 13.41 ± 29.98 | 143.97 ± 427.01 |
| Week 8 | 14.21 ± 26.82 | 111.44 ± 280.34 |
| Week 16 | 15.40 ± 24.26 | 66.20 ± 70.50 |
| Week 24 | 11.81 ± 24.05 | 62.74 ± 53.40 |
| Week 36 | 9.32 ± 15.23 | 62.15 ± 68.08 |
| Week 48 | 9.25 ± 15.14 | 53.98 ± 57.25 |
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
| pg/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 5.21 (0.0 to 15.0) | 4.65 (0.0 to 419.0) |
| Week 4 | 5.31 (0.0 to 246.0) | 56.50 (0.0 to 3260.0) |
| Week 8 | 5.15 (0.0 to 214.0) | 58.65 (0.0 to 2650.0) |
| Week 16 | 5.01 (0.0 to 117.0) | 48.25 (0.0 to 494.0) |
| Week 24 | 3.53 (0.0 to 151.0) | 47.90 (0.0 to 286.0) |
| Week 36 | 4.01 (0.0 to 107.0) | 46.30 (14.8 to 608.0) |
| Week 48 | 3.85 (0.0 to 80.5) | 43.45 (0.0 to 439.0) |
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
| pg/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Week 4 | 1.11 ± 28.78 | 130.60 ± 395.93 |
| Week 8 | 2.43 ± 31.00 | 97.22 ± 237.43 |
| Week 16 | 3.07 ± 31.71 | 57.10 ± 62.62 |
| Week 24 | 0.13 ± 30.63 | 53.33 ± 46.81 |
| Week 36 | -3.48 ± 23.23 | 52.26 ± 55.81 |
| Week 48 | -1.60 ± 21.54 | 40.01 ± 29.89 |
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
| pg/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Week 4 | -0.12 (-150.0 to 202.7) | 52.41 (-27.4 to 2841.0) |
| Week 8 | 0.83 (-148.6 to 210.5) | 52.35 (-9.8 to 2231.0) |
| Week 16 | 0.34 (-148.5 to 114.5) | 42.35 (-6.0 to 494.0) |
| Week 24 | 0.00 (-148.5 to 144.9) | 41.21 (-8.0 to 284.0) |
| Week 36 | 0.00 (-148.2 to 63.3) | 41.20 (0.9 to 474.0) |
| Week 48 | 0.00 (-150.0 to 46.0) | 32.96 (-11.8 to 138) |
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
| ng/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 42.16 ± 32.41 | 42.22 ± 14.56 |
| Week 4 | 46.07 ± 73.52 | 486.58 ± 122.94 |
| Week 8 | 45.71 ± 57.95 | 546.59 ± 142.58 |
| Week 16 | 47.81 ± 68.22 | 583.87 ± 164.36 |
| Week 24 | 41.35 ± 15.17 | 587.28 ± 153.90 |
| Week 36 | 38.13 ± 11.22 | 589.59 ± 140.63 |
| Week 48 | 49.27 ± 76.97 | 571.48 ± 167.85 |
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
| ng/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 37.10 (17.0 to 340.0) | 39.00 (20.1 to 97.2) |
| Week 4 | 38.10 (19.4 to 775.0) | 482.50 (42.0 to 773.0) |
| Week 8 | 37.20 (17.6 to 612.0) | 536.00 (30.5 to 873.0) |
| Week 16 | 38.95 (20.6 to 711.0) | 589.50 (27.4 to 1290.0) |
| Week 24 | 39.30 (19.5 to 99.8) | 590.00 (23.2 to 945.0) |
| Week 36 | 36.20 (21.1 to 67.5) | 591.00 (45.4 to 970.0) |
| Week 48 | 36.00 (19.2 to 596.0) | 576.50 (23.4 to 973.0) |
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
| ng/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Week 4 | 3.96 ± 79.00 | 444.23 ± 120.90 |
| Week 8 | 3.31 ± 65.47 | 501.09 ± 140.42 |
| Week 16 | 6.04 ± 77.69 | 539.21 ± 165.63 |
| Week 24 | -1.29 ± 35.46 | 540.98 ± 152.70 |
| Week 36 | -4.31 ± 35.92 | 544.89 ± 142.95 |
| Week 48 | 7.23 ± 86.81 | 525.66 ± 165.53 |
Serum soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
| ng/mL | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Week 4 | 0.20 (-318.4 to 709.5) | 437.80 (-13.4 to 724.3) |
| Week 8 | 0.20 (-305.9 to 560.8) | 489.90 (-14.1 to 823.0) |
| Week 16 | 0.25 (-316.4 to 679.0) | 542.30 (-28.0 to 1248.7) |
| Week 24 | 1.20 (-316.6 to 51.6) | 547.50 (-32.2 to 909.9) |
| Week 36 | -0.40 (-315.7 to 24.1) | 541.70 (-26.6 to 942.9) |
| Week 48 | -0.70 (-317.9 to 560.2) | 532.20 (-0.4 to 945.9) |
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
| mg/L | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 7.43 ± 12.61 | 9.00 ± 14.76 |
| Week 4 | 9.81 ± 20.79 | 0.85 ± 2.52 |
| Week 24 | 9.89 ± 13.99 | 0.56 ± 1.19 |
| Week 48 | 7.52 ± 12.80 | 1.58 ± 6.22 |
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
| mg/L | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 3.82 (1.19 to 8.69) | 4.05 (1.30 to 9.48) |
| Week 4 | 3.71 (1.27 to 8.83) | 0.20 (0.20 to 0.50) |
| Week 24 | 4.15 (1.43 to 13.10) | 0.20 (0.20 to 0.47) |
| Week 48 | 3.67 (1.26 to 7.78) | 0.20 (0.20 to 0.59) |
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
| ug/mL | Double-Blind Tocilizumab |
|---|---|
| Baseline | 0.00 ± 0.03 |
| Week 4 | 30.92 ± 15.24 |
| Week 8 | 41.82 ± 17.66 |
| Week 16 | 50.98 ± 23.33 |
| Week 24 | 54.34 ± 26.24 |
| Week 36 | 53.55 ± 29.25 |
| Week 48 | 54.67 ± 29.79 |
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
| ug/mL | Double-Blind Tocilizumab |
|---|---|
| Baseline | 0.00 (0.0 to 0.2) |
| Week 4 | 28.70 (0.4 to 86.8) |
| Week 8 | 39.25 (8.3 to 97.6) |
| Week 16 | 47.40 (9.5 to 120.0) |
| Week 24 | 52.60 (7.6 to 117.0) |
| Week 36 | 52.50 (4.0 to 138.0) |
| Week 48 | 52.10 (0.4 to 145.0) |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 20.4 ± 6.95 | 20.3 ± 5.56 |
| Week 8 | 18.6 ± 7.78 | 17.9 ± 5.84 |
| Week 16 | 17.9 ± 8.71 | 16.2 ± 5.58 |
| Week 24 | 16.9 ± 9.38 | 14.7 ± 5.61 |
| Week 36 | 16.2 ± 10.24 | 13.2 ± 4.97 |
| Week 48 | 14.8 ± 9.89 | 12.2 ± 6.03 |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 19.0 (10 to 40) | 20.0 (11 to 31) |
| Week 8 | 18.0 (4 to 43) | 16.0 (9 to 34) |
| Week 16 | 17.0 (0 to 38) | 15.0 (8 to 30) |
| Week 24 | 16.0 (0 to 42) | 14.0 (6 to 29) |
| Week 36 | 14.0 (0 to 47) | 13.5 (5 to 27) |
| Week 48 | 14.0 (0 to 43) | 12.5 (2 to 30) |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 20.4 ± 6.95 | 19.1 ± 6.24 |
| Week 8 | 18.6 ± 7.78 | 17.2 ± 6.17 |
| Week 16 | 17.9 ± 8.71 | 16.2 ± 6.10 |
| Week 24 | 16.9 ± 9.38 | 14.6 ± 6.66 |
| Week 36 | 16.2 ± 10.24 | 13.4 ± 6.20 |
| Week 48 | 14.8 ± 9.89 | 11.6 ± 5.72 |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 19.0 (10 to 40) | 18.0 (10 to 35) |
| Week 8 | 18.0 (4 to 43) | 17.0 (5 to 31) |
| Week 16 | 17.0 (0 to 38) | 16.0 (5 to 27) |
| Week 24 | 16.0 (0 to 42) | 14.0 (3 to 28) |
| Week 36 | 14.0 (0 to 47) | 13.0 (2 to 25) |
| Week 48 | 14.0 (0 to 43) | 11.0 (0 to 24) |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 20.4 ± 6.95 | 19.8 ± 6.82 |
| Week 8 | 18.6 ± 7.78 | 17.9 ± 7.35 |
| Week 16 | 17.9 ± 8.71 | 16.7 ± 7.31 |
| Week 24 | 16.9 ± 9.38 | 15.6 ± 7.50 |
| Week 36 | 16.2 ± 10.24 | 13.7 ± 7.07 |
| Week 48 | 14.8 ± 9.89 | 12.8 ± 7.20 |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Baseline | 19.0 (10 to 40) | 19.0 (11 to 33) |
| Week 8 | 18.0 (4 to 43) | 17.5 (5 to 32) |
| Week 16 | 17.0 (0 to 38) | 15.0 (6 to 33) |
| Week 24 | 16.0 (0 to 42) | 15.0 (2 to 31) |
| Week 36 | 14.0 (0 to 47) | 11.0 (4 to 30) |
| Week 48 | 14.0 (0 to 43) | 11.0 (4 to 34) |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Low Exposure | -5.3 ± 7.77 | -8.0 ± 5.85 |
| Medium Exposure | -5.3 ± 7.77 | -7.5 ± 5.06 |
| High Exposure | -5.3 ± 7.77 | -7.0 ± 6.26 |
In order to characterize exposure-efficacy relationships, mRSS scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Units on a scale | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Low Exposure | -5.5 (-25 to 22) | -8.0 (-19 to 4) |
| Medium Exposure | -5.5 (-25 to 22) | -7.0 (-18 to 2) |
| High Exposure | -5.5 (-25 to 22) | -6.0 (-20 to 6) |
In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Percent | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Low Exposure | -4.264 ± 8.155 | 0.144 ± 6.474 |
| Medium Exposure | -4.264 ± 8.155 | -0.161 ± 6.440 |
| High Exposure | -4.264 ± 8.155 | -0.297 ± 7.895 |
In order to characterize exposure-efficacy relationships, ppFVC scores are summarized based on TCZ exposure tertiles (high, medium, and low exposures) in the active treatment group and compared to placebo patients. Low Exposure = 0-\<41 ug/ml, Medium = 41-\<=61.1 ug/ml, High = 61.1-\<=145 ug/ml.
| Percent | Double-Blind Placebo | Double-Blind Tocilizumab |
|---|---|---|
| Low Exposure | -3.910 (-31.47 to 13.47) | 0.525 (-14.25 to 11.38) |
| Medium Exposure | -3.910 (-31.47 to 13.47) | -1.600 (-13.83 to 17.00) |
| High Exposure | -3.910 (-31.47 to 13.47) | 0.000 (-10.55 to 19.69) |
Summary of key safety results including Adverse Events of Special Interest (AESI). All adverse events categorized according to MedDRA version 21.1. NMSC = Non-Melanoma Skin Cancer
| Percentage of participants | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| At least one Adverse Event (AE) | 77.4 | 85.6 | 77.5 | 71.7 |
| Withdrawn from study due to an AE | 12.3 | 6.7 | 1.1 | 1.1 |
| Fatal AE | 2.8 | 1.0 | 1.1 | 1.1 |
| Serious Adverse Events (SAEs) | 17.0 | 12.5 | 7.9 | 10.9 |
| SAE leading to withdrawal from treatment | 5.7 | 4.8 | 1.1 | 1.1 |
| SAE leading to dose modification/interruption | 5.7 | 2.9 | 4.5 | 3.3 |
| SAE related to study drug | 6.6 | 1.0 | 3.4 | 3.3 |
| AE leading to withdrawal from treatment | 12.3 | 6.7 | 1.1 | 1.1 |
| AE leading to dose modification/interruption | 26.4 | 19.2 | 28.1 | 22.8 |
| AE related to study drug | 34.0 | 46.2 | 33.7 | 34.8 |
| Related AE leading to withdrawal from treatment | 1.9 | 1.0 | 1.1 | 1.1 |
| Related AE with dose modification/interruption | 17.0 | 11.5 | 12.4 | 14.1 |
| Serious Infections and Infestations AEs | 6.6 | 1.9 | 3.4 | 1.1 |
| Infections and Infestations AEs | 50.0 | 52.9 | 46.1 | 39.1 |
| Opportunistic Infections AEs | 0.9 | 1.0 | 0 | 1.1 |
| Malignancy AEs | 0.9 | 1.9 | 0 | 1.1 |
| Malignancy AEs (excluding NMSC) | 0.9 | 1.9 | 0 | 1.1 |
| Serious Hepatic AEs | 0 | 0 | 0 | 0 |
| Serious Stroke AEs | 0 | 0 | 0 | 0 |
| Serious Myocardial Infarction AEs | 1.9 | 0 | 0 | 0 |
| Anaphylactic Reaction AEs | 0 | 0 | 0 | 0 |
| Anaphylactic Reaction AEs (Sampson's Criteria) | 0 | 0 | 0 | 0 |
| Serious Gastrointestinal Perforation AEs | 0 | 0 | 0 | 0 |
| Serious Bleeding AEs | 0.9 | 0 | 0 | 0 |
| Serious Demyelinating AEs | 0 | 0 | 0 | 0 |
Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) severity grade: 1 = mild, 2 = moderate, 3 = severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening consequences, and 5 = death.
| Number of participants | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| Grade 1 | 61 | 78 | 60 | 53 |
| Grade 2 | 63 | 53 | 41 | 35 |
| Grade 3 | 21 | 18 | 9 | 8 |
| Grade 4 | 7 | 0 | 4 | 5 |
| Grade 5 | 3 | 1 | 1 | 1 |
| Number of participants | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| CARDIAC FAILURE CHRONIC | 1 | 0 | 0 | 0 |
| MYOCARDITIS | 1 | 0 | 0 | 0 |
| MYOCARDIAL INFARCTION | 1 | 0 | 0 | 0 |
| DEATH | 0 | 1 | 0 | 0 |
| BRAIN INJURY | 0 | 0 | 1 | 0 |
| PULMONARY HYPERTENSION | 0 | 0 | 0 | 1 |
A digital ulcer is defined as an ulcer at or distal to the MCP joint on either the dorsal or volar surface, with loss of surface epithelialization. This does not include fissures, cracks, or calcium extrusions from calcinosis cutis. The number of fingers (0-10) with digital ulcers and the number of digital (or finger) ulcers will be counted and recorded by the investigator.
| Percentage of participants | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| No change | 0 | 0 | 91.1 | 83.3 |
| Increase by 1 | 0 | 0 | 0 | 4.8 |
| Increase by 2 | 0 | 0 | 0 | 1.2 |
| Increase by 3 | 0 | 0 | 0 | 1.2 |
| Increase by 4 | 0 | 0 | 0 | 0 |
| Increase by >4 | 0 | 0 | 0 | 1.2 |
| Decrease by 1 | 0 | 0 | 3.8 | 4.8 |
| Decrease by 2 | 0 | 0 | 2.5 | 0 |
| Decrease by 3 | 0 | 0 | 1.3 | 1.2 |
| Decrease by 4 | 0 | 0 | 1.3 | 1.2 |
| Decrease by >4 | 0 | 0 | 0 | 0 |
| Baseline missing | 0 | 0 | 0 | 1.2 |
Reported were the percentage of participants with post-baseline treatment-induced anti-TCZ antibodies. Positive samples underwent additional analyses: a neutralizing assay for the ability to inhibit the activity of TCZ and a test for anti -TCZ of the IgE isotype.
| Percentage of Participants | Tocilizumab, Then Tocilizumab Open Label |
|---|---|
| Treatment-Induced Anti-TCZ Antibodies | 0.0 |
| Anti-TCZ Antibodies of Neutralizing Potential | 0.0 |
| Anti-TCZ Antibodies of IgE | 0.0 |
Erythrocyte Sedimentation Rate (ESR) levels predose at baseline and at subsequent time points after initiation of study drug.
| mm/hr | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| Baseline | 34.72 ± 18.49 | 34.83 ± 16.29 | — | — |
| Week 4 | 31.38 ± 19.00 | 14.29 ± 12.98 | — | — |
| Week 24 | 28.49 ± 20.86 | 8.46 ± 8.63 | — | — |
| Week 48 | 26.23 ± 18.53 | 10.89 ± 15.39 | — | — |
| Week 72 | — | — | 9.54 ± 9.47 | 8.29 ± 10.13 |
| Week 96 | — | — | 9.67 ± 8.67 | 8.06 ± 8.86 |
Serum Interleukin (IL)-6 levels predose at baseline and at subsequent time points after initiation of study drug.
| pg/mL | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| Baseline | 11.85 ± 19.73 | 13.86 ± 43.78 | — | — |
| Week 4 | 13.41 ± 29.98 | 144.75 ± 429.14 | — | — |
| Week 8 | 14.21 ± 26.82 | 111.44 ± 280.34 | — | — |
| Week 16 | 15.40 ± 24.26 | 66.20 ± 70.50 | — | — |
| Week 24 | 11.81 ± 24.05 | 62.74 ± 53.40 | — | — |
| Week 36 | 9.32 ± 15.23 | 62.15 ± 68.08 | — | — |
| Week 48 | 9.10 ± 14.88 | 53.34 ± 56.80 | — | — |
| Week 96 | — | — | 62.60 ± 57.21 | 52.03 ± 46.51 |
Serum Soluble Interleukin (IL)-6 receptor levels predose at baseline and at subsequent time points after initiation of study drug.
| ng/mL | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| Baseline | 42.23 ± 32.56 | 42.15 ± 14.50 | — | — |
| Week 4 | 46.07 ± 73.52 | 487.70 ± 123.02 | — | — |
| Week 8 | 45.71 ± 57.95 | 546.59 ± 142.58 | — | — |
| Week 16 | 47.81 ± 68.22 | 583.87 ± 164.36 | — | — |
| Week 24 | 41.35 ± 15.17 | 587.28 ± 153.90 | — | — |
| Week 36 | 38.13 ± 11.22 | 589.59 ± 140.63 | — | — |
| Week 48 | 49.51 ± 76.17 | 566.49 ± 175.25 | — | — |
| Week 96 | — | — | 558.38 ± 256.86 | 565.31 ± 159.82 |
Serum C-Reactive Protein (CRP) levels predose at baseline and at subsequent time points after initiation of study drug.
| mg/L | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| Baseline | 7.42 ± 12.62 | 8.99 ± 14.76 | — | — |
| Week 4 | 10.05 ± 20.82 | 0.85 ± 2.50 | — | — |
| Week 24 | 9.89 ± 13.99 | 0.56 ± 1.19 | — | — |
| Week 48 | 7.40 ± 12.62 | 1.75 ± 6.43 | — | — |
| Week 72 | — | — | 0.57 ± 0.80 | 0.92 ± 3.61 |
| Week 96 | — | — | 0.90 ± 2.73 | 0.97 ± 5.08 |
Predose observed serum TCZ concentration at baseline and at specified timepoints thereafter
| ug/mL | Double-Blind Tocilizumab, Then Open Label Tocilizumab |
|---|---|
| Baseline | 0.00 ± 0.03 |
| Week 4 | 30.76 ± 15.23 |
| Week 8 | 41.82 ± 17.66 |
| Week 16 | 50.98 ± 23.33 |
| Week 24 | 54.34 ± 26.24 |
| Week 36 | 53.55 ± 29.25 |
| Week 48 | 54.87 ± 29.69 |
| Week 96 | 49.99 ± 26.19 |
Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Placebo | 3/106 (2.8%) | 18/106 (17%) | 59/106 (55.7%) |
| Double-Blind Tocilizumab | 1/104 (1%) | 13/104 (12.5%) | 60/104 (57.7%) |
| Placebo, Then Tocilizumab Open Label | 1/89 (1.1%) | 7/89 (7.9%) | 46/89 (51.7%) |
| Tocilizumab, Then Tocilizumab Open Label | 1/92 (1.1%) | 10/92 (10.9%) | 28/92 (30.4%) |
| Event | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 3/106 | 0/104 | 1/89 | 1/92 |
| ARRHYTHMIACardiac disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| CARDIAC TAMPONADECardiac disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| RECTAL PROLAPSEGastrointestinal disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| INFECTIVE TENOSYNOVITISInfections and infestations | 0/106 | 0/104 | 1/89 | 0/92 |
| SEPSISInfections and infestations | 1/106 | 0/104 | 1/89 | 0/92 |
| FEMORAL NECK FRACTUREInjury, poisoning and procedural complications | 0/106 | 0/104 | 1/89 | 0/92 |
| TENDONITISMusculoskeletal and connective tissue disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| BRAIN INJURYNervous system disorders | 0/106 | 0/104 | 1/89 | 0/92 |
| Event | Double-Blind Placebo | Double-Blind Tocilizumab | Placebo, Then Tocilizumab Open Label | Tocilizumab, Then Tocilizumab Open Label |
|---|---|---|---|---|
| SKIN ULCERSkin and subcutaneous tissue disorders | 12/106 | 15/104 | 16/89 | 11/92 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 14/106 | 12/104 | 3/89 | 5/92 |
| NASOPHARYNGITISInfections and infestations | 8/106 | 13/104 | 9/89 | 4/92 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 11/106 | 12/104 | 10/89 | 4/92 |
| URINARY TRACT INFECTIONInfections and infestations | 10/106 | 5/104 | 7/89 | 1/92 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 6/106 | 4/104 | 8/89 | 2/92 |
| FATIGUEGeneral disorders | 7/106 | 8/104 | 0/89 | 0/92 |
| INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders | 8/106 | 2/104 | 1/89 | 1/92 |
| DIARRHOEAGastrointestinal disorders | 7/106 | 6/104 | 6/89 | 5/92 |
| GASTROENTERITISInfections and infestations | 2/106 | 7/104 | 0/89 | 3/92 |
The analysis was conducted on the safety population, i.e. all randomized patients who received at least one dose of study drug and provided data from at least one post dose safety assessment.
| Age, Continuous(Years) | Double-Blind Placebo, Then Tocilizumab Open Label | Double-Blind Tocilizumab, Then Tocilizumab Open Label | Total |
|---|---|---|---|
| Mean | 49.3 ± 12.6 | 47.0 ± 12.2 | 48.2 ± 12.4 |
| Sex: Female, Male(Participants) | Double-Blind Placebo, Then Tocilizumab Open Label | Double-Blind Tocilizumab, Then Tocilizumab Open Label | Total |
|---|---|---|---|
| Female | 90 | 81 | 171 |
| Male | 16 | 23 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Placebo, Then Tocilizumab Open Label | Double-Blind Tocilizumab, Then Tocilizumab Open Label | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 13 | 39 |
| Not Hispanic or Latino | 79 | 89 | 168 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Double-Blind Placebo, Then Tocilizumab Open Label | Double-Blind Tocilizumab, Then Tocilizumab Open Label | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 9 | 16 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 90 | 85 | 175 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Jan 2018, 25 months.
Results were first posted in Apr 2019, 1 year 2 months after primary completion.
Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab